BPC-157 research: what the literature actually says
A large preclinical literature, a thin human one — and a regulatory framework that reflects exactly that pattern.
TL;DR
- The peer-reviewed BPC-157 literature is substantial in volume but dominated by preclinical animal studies, with limited human clinical trial data.
- Findings are reasonably consistent across animal models — particularly in tendon repair, gut mucosal protection, and induced injury healing — but a substantial fraction of the literature comes from a single research group.
- The thin human evidence base is one of the central reasons FDA placed BPC-157 in Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn.
What it is
The BPC-157 research base spans more than 25 years of peer-reviewed publications, beginning with the early 1990s work that identified the parent Body Protection Compound in human gastric juice (Sikiric et al., Journal of Physiology - Paris, 1993). PubMed indexes hundreds of peer-reviewed papers on BPC-157 across mechanism, tissue-repair, gastrointestinal, neurological, and cardiovascular models.
Where the evidence is strong
The strongest part of the evidence base is in animal models. Studies — most prominently in rats — have reported reasonably consistent effects in tendon healing, gastric and intestinal ulcer models, induced colitis, vascular injury, and various other tissue-injury contexts. The proposed mechanisms (VEGF-mediated angiogenesis, nitric oxide signaling, growth factor upregulation) are reproduced across multiple studies and are biologically plausible (Sikiric et al., Current Pharmaceutical Design, 2018).
Where the evidence is limited
Three significant limitations are worth naming directly. First, human trial data is sparse. Robust randomized human trials of BPC-157 for any specific indication are not currently available in the published literature. Second, publication concentration. A substantial fraction of the BPC-157 research has come from one Croatian research group; while the work is peer-reviewed, independent replication outside that group is more limited. Third, pharmacokinetics in humans. Basic questions about absorption, distribution, metabolism, and excretion of BPC-157 in humans — including the specifics of oral vs subcutaneous bioavailability — have not been characterized at the level expected of compounds entering routine clinical use.
Who asks about it
People come to this topic when they have read enthusiastic claims about BPC-157 online and want a more measured summary, or when they have read dismissive claims and want to know whether anything is actually there. Both audiences are looking for the same answer: an honest read of what the literature shows.
What the research says
The most useful single-sentence summary of the BPC-157 literature is this: there is enough preclinical signal to take the molecule seriously as a research target, and not enough human evidence to take it as established clinical therapy. That was the assessment reflected in the FDA's 2023 Category 2 placement.
What to know before considering it
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. The regulatory landscape is moving. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. The evidence base itself remains as described here.
The Halftime POV
We think the BPC-157 research deserves to be described accurately rather than enthusiastically or dismissively. The animal literature is substantial. The human literature is thin. The regulatory framework reflects that gap. All three statements are true at once, and a good educational article should hold them all without flattening any of them.
Related reading:
- BPC-157: what this body protection compound actually is
- How BPC-157 works: the mechanism behind the research
- BPC-157 side effects and safety profile
FAQ
Q: Are there human clinical trials of BPC-157? A: Robust randomized human clinical trials of BPC-157 are not currently available in the published literature. The peer-reviewed evidence base is dominated by preclinical studies in rats and mice. The absence of robust human trial data was one of the central reasons FDA placed BPC-157 in Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn.
Q: Where is the BPC-157 evidence strongest? A: The strongest part of the BPC-157 evidence base is the volume and consistency of animal model findings — particularly in tendon repair, gastric ulcer healing, and inflammatory bowel models. The mechanism proposals (angiogenesis, nitric oxide signaling, growth factor upregulation) are also reasonably consistent across studies.
Q: What are the main critiques of the BPC-157 research? A: Critiques include: heavy concentration of publications from a single research group, limited independent replication of some findings, almost no published human pharmacology or efficacy trials, and a lack of standardized dosing or pharmacokinetic data in humans. These factors informed FDA's 2023 placement of BPC-157 in Category 2.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational only and is not medical advice.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Sikiric P, et al. A new gastric juice peptide, BPC. Journal of Physiology - Paris, 1993.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 2018.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Are there human clinical trials of BPC-157?
Robust randomized human clinical trials of BPC-157 are not currently available in the published literature. The peer-reviewed evidence base is dominated by preclinical studies in rats and mice. The absence of robust human trial data was one of the central reasons FDA placed BPC-157 in Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn.
Where is the BPC-157 evidence strongest?
The strongest part of the BPC-157 evidence base is the volume and consistency of animal model findings — particularly in tendon repair, gastric ulcer healing, and inflammatory bowel models. The mechanism proposals (angiogenesis, nitric oxide signaling, growth factor upregulation) are also reasonably consistent across studies.
What are the main critiques of the BPC-157 research?
Critiques include: heavy concentration of publications from a single research group, limited independent replication of some findings, almost no published human pharmacology or efficacy trials, and a lack of standardized dosing or pharmacokinetic data in humans. These factors informed FDA's 2023 placement of BPC-157 in Category 2.
Keep reading
Buying peptides online? There is a route with labs first and a licensed physician.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.